2024 Sunnybrook – Entire Hospital (Gram Positive and Gram Negative)
2024 Sunnybrook - Entire HospitalDuplicate isolates within 30 days, surveillance and urine specimens excluded
| Gram Positive |
Total Isolates |
% of isolates susceptible |
| Ampicillin |
Ceftriaxone |
Clindamycin |
Cloxacillin* |
Penicillin |
TMP/SMX |
Vancomycin |
| Coagulase Negative Staphylococci |
322 |
|
|
57% |
39% |
|
68% |
100% |
| Enterococcus faecalis |
158 |
99% |
|
R |
|
|
R |
100% |
| Enterococcus faecium |
74 |
25% |
|
R |
|
|
R |
86% |
| Staphylococcus aureus |
964 |
|
|
79% |
82% |
|
98% |
100% |
| MRSA |
175 |
|
|
75% |
R |
|
94% |
100% |
| MSSA |
789 |
|
|
79% |
100% |
|
99% |
100% |
| Streptococcus pneumoniae |
40 |
|
100% |
|
|
100% |
|
100% |
| Viridans Streptococci |
125 |
|
99% |
|
|
93% |
|
100% |
*Staphylococci that test susceptible to cloxacillin are also susceptible to cefazolin
| Gram Negative |
Total Isolates |
% of isolates susceptible |
| Amikacin |
Ampicillin |
Cefazolin |
Ceftazidime |
Ceftriaxone |
Ciprofloxacin |
Gentamicin |
Meropenem |
Piperacillin/tazobactam |
Tobramycin |
TMP/SMX |
| Enterobacter cloacae complex |
179 |
100% |
R |
R |
|
R |
90% |
98% |
99% |
R |
98% |
91% |
| Escherichia coli |
433 |
100% |
42% |
56% |
|
70% |
65% |
91% |
99% |
67% |
90% |
69% |
| ESBL |
126 |
100% |
R |
R |
|
R |
28% |
82% |
99% |
R |
77% |
49% |
| non ESBL |
307 |
100% |
60% |
79% |
|
98% |
79% |
95% |
99% |
94% |
95% |
76% |
| Klebsiella aerogenes |
41 |
100% |
R |
R |
|
R |
95% |
100% |
98% |
R |
100% |
98% |
| Klebsiella oxytoca |
47 |
100% |
R |
19% |
|
96% |
98% |
100% |
100% |
96% |
100% |
98% |
| Klebsiella pneumoniae |
237 |
100% |
R |
79% |
|
88% |
80% |
94% |
98% |
84% |
93% |
85% |
| Proteus mirabilis |
65 |
100% |
80% |
14% |
|
95% |
89% |
94% |
97% |
98% |
92% |
86% |
| Pseudomonas aeruginosa |
407 |
|
R |
R |
82% |
R |
84% |
R |
80% |
85% |
99% |
R |
| Serratia marcescens |
83 |
100% |
R |
R |
|
95% |
92% |
100% |
100% |
98% |
89% |
99% |
| Stenotrophomonas maltophilia |
50 |
R |
R |
R |
NA |
R |
|
R |
R |
R |
R |
90% |
R = considered inherently resistant, NA = not available
2024 Sunnybrook – ICU (Gram Positive and Gram Negative)
2024 Sunnybrook - ICU Duplicate isolates within 30 days, surveillance and urine specimens excluded
| Gram Positive |
Total Isolates |
% of isolates susceptible |
|
|
|
|
|
|
|
|
|
|
|
|
| Ampicillin |
Clindamycin |
Cloxacillin |
TMP/SMX |
Vancomycin |
|
|
|
|
|
|
|
|
|
|
|
|
| Coagulase Negative Staphlylococci |
70 |
|
42% |
26% |
54% |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
| Enterococcus faecalis |
31 |
100% |
R |
|
R |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
| Enterococcus faecium |
23^ |
43% |
R |
|
R |
91% |
|
|
|
|
|
|
|
|
|
|
|
|
| Staphylococcus aureus |
171 |
|
77% |
82% |
99% |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
| MRSA |
30 |
|
77% |
R |
100% |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
| MSSA |
141 |
|
77% |
100% |
99% |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
*Staphylococci that test susceptible to cloxacillin are also susceptible to cefazolin
| Gram Negative |
Total Isolates |
% of isolates susceptible |
|
|
|
|
|
|
| Amikacin |
Ampicillin |
Cefazolin |
Ceftazidime |
Ceftriaxone |
Ciprofloxacin |
Gentamicin |
Meropenem |
Piperacillin/tazobactam |
Tobramycin |
TMP/SMX |
|
|
|
|
|
|
| Enterobacter cloacae complex |
69 |
100% |
R |
R |
|
R |
96% |
100% |
97% |
R |
99% |
94% |
|
|
|
|
|
|
| Escherichia coli |
62 |
100% |
32% |
37% |
|
50% |
53% |
97% |
97% |
47% |
97% |
71% |
|
|
|
|
|
|
| ESBL |
30 |
100% |
R |
R |
|
R |
30% |
93% |
100% |
R |
93% |
60% |
|
|
|
|
|
|
| non ESBL |
32 |
100% |
63% |
72% |
|
94% |
75% |
100% |
94% |
88% |
100% |
81% |
|
|
|
|
|
|
| Klebsiella pneumoniae |
61 |
100% |
R |
75% |
|
84% |
78% |
92% |
98% |
78% |
90% |
84% |
|
|
|
|
|
|
| Pseudomonas aeruginosa |
85 |
|
R |
R |
74% |
R |
81% |
R |
73% |
79% |
100% |
R |
|
|
|
|
|
|
| Serratia marcescens |
31 |
100% |
R |
R |
|
94% |
97% |
100% |
100% |
94% |
87% |
97% |
|
|
|
|
|
|
^ Total number of isolates <30, interpret with caution
R = considered inherently resistant
2024Sunnybrook – Urine (Gram Positive and Gram Negative)
2024 Sunnybrook Urine Antibiogram Duplicate isolates within 30 days excluded
| Gram Positive |
Total Isolates |
% of isolates susceptible |
|
|
|
|
|
|
|
| Ampicillin |
Cloxacillin* |
Nitrofurantoin |
TMP/SMX |
Vancomycin |
|
|
|
|
|
|
|
| Enterococcus faecalis |
687 |
100% |
|
100% |
R |
99% |
|
|
|
|
|
|
|
| Enterococcus faecium |
99 |
16% |
|
44% |
R |
86% |
|
|
|
|
|
|
|
| Staphylococcus aureus |
101 |
|
85% |
100% |
100% |
100% |
|
|
|
|
|
|
|
*Staphylococci that test susceptible to cloxacillin are also susceptible to cefazolin
| Gram Negative |
Total Isolates |
% of isolates susceptible |
| Amikacin |
Ampicillin |
Cefazolin |
Ceftazidime |
Ceftriaxone |
Ciprofloxacin* |
Gentamicin |
Meropenem |
Nitrofurantoin |
Piperacillin/tazobactam |
Tobramycin |
TMP/SMX |
| Citrobacter freundii |
38 |
97% |
R |
R |
|
R |
92% |
97% |
100% |
100% |
R |
97% |
95% |
| Citrobacter koseri |
60 |
100% |
R |
NA |
|
98% |
100% |
100% |
98% |
47% |
100% |
100% |
98% |
| Enterobacter cloacae complex |
160 |
99% |
R |
R |
|
R |
87% |
98% |
97% |
43% |
R |
94% |
88% |
| Escherichia coli |
1632 |
100% |
50% |
67% |
|
80% |
63% |
91% |
100% |
97% |
79% |
89% |
73% |
| ESBL |
333 |
99% |
R |
R |
|
R |
18% |
81% |
99% |
95% |
R |
73% |
45% |
| non ESBL |
1359 |
100% |
62% |
83% |
|
99% |
74% |
93% |
100% |
98% |
98% |
93% |
79% |
| Klebsiella aerogenes |
55 |
100% |
R |
R |
|
R |
94% |
100% |
98% |
40% |
R |
98% |
95% |
| Klebsiella oxytoca |
99 |
100% |
R |
20% |
|
95% |
99% |
99% |
100% |
97% |
95% |
99% |
93% |
| Klebsiella pneumoniae |
483 |
99% |
R |
79% |
|
86% |
81% |
96% |
97% |
58% |
85% |
94% |
85% |
| ESBL |
57 |
98% |
R |
R |
|
R |
16% |
75% |
88% |
37% |
R |
65% |
30% |
| non ESBL |
426 |
99% |
R |
89% |
|
97% |
90% |
98% |
98% |
60% |
96% |
98% |
92% |
| Morganella morganii |
30 |
100% |
R |
R |
|
97% |
83% |
90% |
100% |
R |
100% |
93% |
83% |
| Proteus mirabilis |
185 |
98% |
86% |
7% |
|
96% |
83% |
88% |
99% |
R |
96% |
89% |
89% |
| Pseudomonas aeruginosa |
252 |
100% |
R |
R |
87% |
R |
82% |
R |
89% |
|
91% |
100% |
R |
R= Considered inherently resistant
